Advertisement

Zonisamide for West syndrome: a comparison of clinical responses among different titration rate

      Abstract

      We administered zonisamide (ZNS) to patients with West syndrome in different titration protocols and compared their short-term therapeutic effects. We designed three protocols to raise the serum ZNS concentration (SZC): (1) increase the dose in three steps, from 3 to 10 mg/kg every 3 days, (2) increase the dose from 5 to 10 mg/kg over 3–7 days, and (3) start with 10 mg/kg and maintain this dosage for 2 weeks. The subjects were 23 infants with West syndrome, 8 of whom comprised the 1st group, 5 the 2nd group, and the remaining 10, the 3rd group. As a result, excellent and good effects were obtained in a total of seven patients (30.4%) and one patient, respectively (1/8 in the 1st step-up group, 3/5 in the 2nd step-up group, and 4/10 in the 3rd group). The maximum SZC was higher in the excellent and good effect groups (n=8; 32.0±8.0 μg/ml) than in the ineffective group (n=15; 22.4±8.2 μg/ml) (P<0.05). The period of time required for cessation of spasms appeared shorter in the 3rd group (n=4; mean=5.7 days) than in the 1st and 2nd groups (n=4; mean=10.3 days). There were few side effects except for transient hyperthermia and gastrointestinal symptoms. Our new protocol of starting with 10 mg/kg of ZNS can be introduced safely and make a therapeutic judgment feasible within 2 weeks.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brain and Development
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Yanagihara K.
        • Imai K.
        • Otani K.
        • Futagi Y.
        The effect of zonisamide in West syndrome (in Japanese).
        No To Hattatsu (Tokyo). 1995; 27: 500-502
        • Yanai S.
        • Hanai T.
        • Narazaki O.
        Treatment of infantile spasms with zonisamide.
        Brain Dev. 1999; 21: 157-161
        • Suzuki Y.
        Zonisamide in West syndrome.
        Brain Dev. 2001; 23: 658-661
        • Suzuki Y.
        • Imai K.
        • Toribe Y.
        • Ueda H.
        • Yanagihara K.
        • Shimono K.
        • et al.
        Long-term response to zonisamide in patients with West syndrome.
        Neurology. 2002; 58: 1556-1559
        • Takauchi T.
        • Kasugai K.
        • Okado N.
        • Takeuchi K.
        • Shiono T.
        • Toda T.
        Measurement of serum concentration and TDM of ZNS by enzyme immunoassay (in Japanese).
        Med Drug J. 1992; 28: 327-331
        • Dulac O.
        • Plouin P.
        • Schlumberger E.
        Infantile spasms.
        in: Wyllie E. The treatment of epilepsy. 3rd ed. Lippincott/Williams & Wilkins, Philadelphia, PA2002: 415-452
        • Oguni H.
        • Hayashi K.
        • Fukuyama Y.
        • Iinuma K.
        • Seki T.
        • Seino S.
        • et al.
        Phase III study of a new antiepileptic drug AD-810, zonisamide in childhood epilepsy (in Japanese).
        Jpn J Pediatr. 1988; 41: 439-450
        • Hashimoto Y.
        • Odani A.
        • Tanigawara Y.
        • Yasuhara M.
        • Okuno T.
        • Hori R.
        Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients.
        Biol Pharm Bull. 1994; 17: 323-326
        • Yoshida R.
        High dose pyridoxal phosphate therapy for West syndrome: clinical; study of 59 patients with special attention to side effects (in Japanese).
        J Tokyo Women Med Coll. 1993; 63: 1156-1184
        • Okumura A.
        • Hayakawa F.
        • Kuno K.
        • Watanabe K.
        Oligohidrosis caused by Zonisamide (in Japanese).
        No To Hattatsu. 1996; 28: 44-47